Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 201,581 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 30,421 · Balance 201,581 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2036-06-16 | Direct | 49,579 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 49,579 · Balance 49,579 F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2023 Filed Dec 28, 2023 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 5,000 | $2.14 | $10,710.00 |
DisclosureSEC source: 0001209191-23-059910 · doc4.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 21:36 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-056908 · doc4.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,617 Underlying: Common Stock · 5,000 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F3 · derivative.exercise_date: The shares underlying this option vested monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 21:36 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 5,000 | $4.59 | $22,950.00 |
DisclosureSEC source: 0001209191-23-056908 · doc4.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.52 to $4.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 21:36 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 5,000 | $2.14 | $10,710.00 |
DisclosureSEC source: 0001209191-23-056908 · doc4.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:48 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 1,283 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-055540 · doc4.xml · derivative · entry 5 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,617 Underlying: Common Stock · 1,283 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F4 · derivative.exercise_date: The shares underlying this option vested monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:48 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 8,717 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-23-055540 · doc4.xml · derivative · entry 4 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,717 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F3 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on February 20, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:48 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 10,000 | $3.71 | $37,100.00 |
DisclosureSEC source: 0001209191-23-055540 · doc4.xml · nonDerivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.70 to $3.725, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:48 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 1,283 | $2.14 | $2,748.19 |
DisclosureSEC source: 0001209191-23-055540 · doc4.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:48 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 8,717 | $1.64 | $14,304.60 |
DisclosureSEC source: 0001209191-23-055540 · doc4.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| August 30, 2023 Filed Aug 30, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 2,841 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-23-047756 · doc4.xml · derivative · entry 9 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,717 Underlying: Common Stock · 2,841 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F4 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on February 20, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 30, 2023 Filed Aug 30, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 2,841 | $3.70 | $10,511.70 |
DisclosureSEC source: 0001209191-23-047756 · doc4.xml · nonDerivative · entry 6 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.70 to $3.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2023 Filed Aug 30, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 2,841 | $1.64 | $4,662.08 |
DisclosureSEC source: 0001209191-23-047756 · doc4.xml · nonDerivative · entry 5 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 2,059 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-23-047756 · doc4.xml · derivative · entry 8 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,558 Underlying: Common Stock · 2,059 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F4 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on February 20, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 2,059 | $3.70 | $7,618.30 |
DisclosureSEC source: 0001209191-23-047756 · doc4.xml · nonDerivative · entry 4 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.70 to $3.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 2,059 | $1.64 | $3,378.82 |
DisclosureSEC source: 0001209191-23-047756 · doc4.xml · nonDerivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 100 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-23-047756 · doc4.xml · derivative · entry 7 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,617 Underlying: Common Stock · 100 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F4 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on February 20, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 100 | $3.70 | $370.00 |
DisclosureSEC source: 0001209191-23-047756 · doc4.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 100 | $1.64 | $164.10 |
DisclosureSEC source: 0001209191-23-047756 · doc4.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 20:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-23-043689 · doc4.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,717 Underlying: Common Stock · 5,000 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F3 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on February 20, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 20:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 5,000 | $4.75 | $23,750.00 |
DisclosureSEC source: 0001209191-23-043689 · doc4.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.72 to $4.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 20:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 5,000 | $1.64 | $8,205.00 |
DisclosureSEC source: 0001209191-23-043689 · doc4.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| June 27, 2023 Filed Jun 28, 2023 21:05 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 7,471 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-23-040058 · doc4.xml · derivative · entry 8 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,717 Underlying: Common Stock · 7,471 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F5 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on February 20, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 27, 2023 Filed Jun 28, 2023 21:05 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 7,471 | $4.39 | $32,797.69 |
DisclosureSEC source: 0001209191-23-040058 · doc4.xml · nonDerivative · entry 5 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.355 to $4.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2023 Filed Jun 28, 2023 21:05 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 7,471 | $1.64 | $12,259.91 |
DisclosureSEC source: 0001209191-23-040058 · doc4.xml · nonDerivative · entry 4 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 21:05 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 712 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-23-040058 · doc4.xml · derivative · entry 7 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,188 Underlying: Common Stock · 712 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F5 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on February 20, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 21:05 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 6,817 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001209191-23-040058 · doc4.xml · derivative · entry 6 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,817 shares Expires 2026-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 21:05 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 7,529 | $4.49 | $33,805.21 |
DisclosureSEC source: 0001209191-23-040058 · doc4.xml · nonDerivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.44 to $4.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 21:05 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 712 | $1.64 | $1,168.39 |
DisclosureSEC source: 0001209191-23-040058 · doc4.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 21:05 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 6,817 | $0.98 | $6,701.11 |
DisclosureSEC source: 0001209191-23-040058 · doc4.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 21:22 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-23-039455 · doc4.xml · derivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This annual option grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this option vest on June 22, 2024, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 29, 2022 Filed Jul 8, 2022 20:02 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 26,900 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-22-041606 · doc4.xml · derivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,900 Underlying: Common Stock · 26,900 shares Expires 2032-06-28 F1 · derivative.exercise_date: This annual option grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this option vest on June 29, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:16 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0001209191-21-050940 · doc4.xml · derivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.